Aptevo Therapeutics (APVO) said Monday that a phase 1 trial of ALG.APV-527 to treat solid tumors has met the trial endpoint of adequate exposure, safety, tolerability and biological activity.
"The interim results from phase 1 trials of ALG.APV-527 are showing encouraging outcomes, particularly in terms of safety and disease stability in the trial patients who were refractory to multiple previous therapies," Thomas Marron, the trial's lead investigator, said in a statement.
Price: 0.2648, Change: +0.01, Percent Change: +2.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.